AC
IMVT icon

Athanor Capital’s Immunovant IMVT Stock Holding History

Athanor Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,419
Closed -$620K – 929
2020
Q4 		$620K Buy
13,419
+4,801
+56% +$222K 0.01% 425
2020
Q3 		$303K Sell
8,618
-7,710
-47% -$232K 0.01% 426
2020
Q2 		$398K Buy
+16,328
New +$350K 0.02% 347
2020
Q1 		– Sell
-500,000
Closed -$7.93M – 241
2019
Q4 		$7.93M Buy
+500,000
New +$5.6M 0.36% 60

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Athanor Capital's IMVT Position: Q1 2021 in Review

Athanor Capital sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 13,419 shares — an estimated $620K sold.

Athanor Capital first reported a position in IMVT in Q4 2019 and held it in 4 quarters. The position peaked at $7.93M in Q4 2019. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

  • Athanor Capital reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 13,419 Immunovant shares in Q1 2021, an estimated $620K.
  • Athanor Capital first reported a position in Immunovant in Q4 2019 and held it in 4 quarters.
  • Athanor Capital's Immunovant position peaked at $7.93M in Q4 2019.
  • 120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.